prikaz prve stranice dokumenta Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
  Preuzmi
PDF 758.17 KB
Znanstveni rad - Izvorni znanstveni rad
Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
Revista médica de Chile, 147 (2019), 5; 557-567. https://doi.org/10.4067/S0034-98872019000500557
Kustić, Domagoj; Lovasić, Franjo; Belac-Lovasić, Ingrid; Avirović, Manuela; Ružić, Alen; Petretić-Majnarić, Silvana

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Kustić, D., Lovasić, F., Belac Lovasić, I., Avirović, M., Ružić, A. i Petretić Majnarić, S. (2019). Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma. Revista médica de Chile, 147. (5), 557-567. doi: 10.4067/S0034-98872019000500557

Kustić, Domagoj, et al. "Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma." Revista médica de Chile, vol. 147, br. 5, 2019, str. 557-567. https://doi.org/10.4067/S0034-98872019000500557

Kustić, Domagoj, Franjo Lovasić, Ingrid Belac Lovasić, Manuela Avirović, Alen Ružić i Silvana Petretić Majnarić. "Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma." Revista médica de Chile 147, br. 5 (2019): 557-567. https://doi.org/10.4067/S0034-98872019000500557

Kustić, D., et al. (2019) 'Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma', Revista médica de Chile, 147(5), str. 557-567. doi: 10.4067/S0034-98872019000500557

Kustić D, Lovasić F, Belac Lovasić I, Avirović M, Ružić A, Petretić Majnarić S. Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma. Revista médica de Chile [Internet]. 05.2019. [pristupljeno 05.06.2024.];147(5):557-567. doi: 10.4067/S0034-98872019000500557

D. Kustić, F. Lovasić, I. Belac Lovasić, M. Avirović, A. Ružić i S. Petretić Majnarić, "Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma", Revista médica de Chile, vol. 147, br. 5, str. 557-567, Svibanj 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:918657. [Citirano: 05.06.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:918657
Podaci o radu
Naslov (engleski)Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
AutorDomagoj Kustić
AutorFranjo Lovasić
AutorIngrid Belac-Lovasić
AutorManuela Avirović
AutorAlen Ružić
AutorSilvana Petretić-Majnarić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za kirurgiju)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za nuklearnu medicinu)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za opću patologiju i patološku anatomiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
BACKGROUND: Breast cancer (BC) is the most common malignancy in women. AIM: To assess the impact of HER2 status on axillary lymph node (ALN) involvement in patients with invasive ductal carcinoma of no special type (IDC-NST) both at diagnosis and during the 4-year postoperative period. PATIENTS AND METHODS: We retrospectively included 375 women with an early clinical stage of non-luminal IDC-NST who between 2007 and 2013 underwent breast surgery at a clinical hospital. They were divided into phenotype-based groups: HR+HER2-, HR+HER2+, HR-HER2+ and HR-HER2-. Only patients with sentinel lymph node (SLN) macrometastases underwent ALN dissection. If > 3 ALNs were positive, radiotherapy was delivered. All patients were treated with chemotherapy, HER2+ BC patients received trastuzumab, and hormone receptor (HR)-positive BC patients received hormonal therapy. RESULTS: Larger tumor size, higher grade, HR+, HER2+ status, and lymphovascular invasion (LVI) were predictive for ALN metastases at diagnosis. The poorest overall, disease-free, and distant recurrence-free survival (OS, DFS, DRFS) were found in the HR-HER2- group, while the poorest locoregional recurrence-free survival (LRFS) was observed in HR-HER2+ and HR-HER2- groups. HER2 status was not predictor of survival. CONCLUSIONS: HER2+ status was predictive for ALN involvement at diagnosis but had no effect on 4-year LRFS in these patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaRevista médica de Chile
Brojčani podacivol. 147, br. 5, str. 557-567
p-ISSN0034-9887
DOIhttps://doi.org/10.4067/S0034-98872019000500557
URN:NBNurn:nbn:hr:184:918657
Datum objave publikacije2019-05
URL dokumentahttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000500557&lng=en&nrm=iso&tlng=en
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2020-03-30 08:06:34